These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37373066)

  • 1. Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival.
    Tumedei MM; Piccinini F; Azzali I; Pirini F; Bravaccini S; De Matteis S; Agostinelli C; Castellani G; Zanoni M; Cortesi M; Vergani B; Leone BE; Righi S; Gazzola A; Casadei B; Gentilini D; Calzari L; Limarzi F; Sabattini E; Pession A; Tazzari M; Bertuzzi C
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
    Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
    Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma.
    Szumera-Ciećkiewicz A; Poleszczuk J; Kuczkiewicz-Siemion O; Paszkiewicz-Kozik E; Rymkiewicz G; Sokół K; Borysiuk A; Kotarska M; Kawecka M; Owczarek D; Pytlak B; Walewski J; Prochorec-Sobieszek M
    Pathol Res Pract; 2020 Oct; 216(10):153096. PubMed ID: 32853965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
    Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
    J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
    Canioni D; Salles G; Mounier N; Brousse N; Keuppens M; Morchhauser F; Lamy T; Sonet A; Rousselet MC; Foussard C; Xerri L
    J Clin Oncol; 2008 Jan; 26(3):440-6. PubMed ID: 18086798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune infiltrate diversity confers a good prognosis in follicular lymphoma.
    Tsakiroglou AM; Astley S; Dave M; Fergie M; Harkness E; Rosenberg A; Sperrin M; West C; Byers R; Linton K
    Cancer Immunol Immunother; 2021 Dec; 70(12):3573-3585. PubMed ID: 33929583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
    Xie M; Jiang Q; Zhao S; Zhao J; Ye X; Qian W
    Int Immunopharmacol; 2020 Aug; 85():106684. PubMed ID: 32540726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.
    Budau L; Wilhelm C; Moll R; Jäkel J; Hirt C; Dölken G; Maschmeyer G; Neubauer E; Strauch K; Burchert A; Herold M; Neubauer A
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2149-2156. PubMed ID: 31273513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
    Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
    J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.
    Xerri L; Huet S; Venstrom JM; Szafer-Glusman E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Laurent C; Gelas-Dore B; Bolen CR; Punnoose E; Bouabdallah R; Brice P; Morschhauser F; Cartron G; Olive D; Salles G;
    Hum Pathol; 2017 Jun; 64():128-136. PubMed ID: 28414090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.
    Sugimoto T; Watanabe T
    J Clin Exp Hematop; 2016; 56(1):1-19. PubMed ID: 27334853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.
    Kridel R; Xerri L; Gelas-Dore B; Tan K; Feugier P; Vawda A; Canioni D; Farinha P; Boussetta S; Moccia AA; Brice P; Chavez EA; Kyle AH; Scott DW; Sanders AD; Fabiani B; Slack GW; Minchinton AI; Haioun C; Connors JM; Sehn LH; Steidl C; Gascoyne RD; Salles G
    Clin Cancer Res; 2015 Aug; 21(15):3428-35. PubMed ID: 25869385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
    Rai S; Inoue H; Sakai K; Hanamoto H; Matsuda M; Maeda Y; Haeno T; Watatani Y; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Espinoza JL; Morita Y; Tanaka H; Ashida T; Tatsumi Y; Nishio K; Matsumura I
    Cancer Sci; 2022 Feb; 113(2):660-673. PubMed ID: 34837284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High inter-follicular spatial co-localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma.
    Hagos YB; Akarca AU; Ramsay A; Rossi RL; Pomplun S; Ngai V; Moioli A; Gianatti A; Mcnamara C; Rambaldi A; Quezada SA; Linch D; Gritti G; Yuan Y; Marafioti T
    Hematol Oncol; 2022 Oct; 40(4):541-553. PubMed ID: 35451108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
    Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
    Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
    Richendollar BG; Pohlman B; Elson P; Hsi ED
    Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.
    Chevalier N; Mueller M; Mougiakakos D; Ihorst G; Marks R; Schmitt-Graeff A; Veelken H
    Leuk Lymphoma; 2016 Sep; 57(9):2150-60. PubMed ID: 26757600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of KLRG1 and CD127 defines distinct CD8
    Wu H; Tang X; Kim HJ; Jalali S; Pritchett JC; Villasboas JC; Novak AJ; Yang ZZ; Ansell SM
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34226281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
    Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
    Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.